Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
Sponsor: National Institutes of Health Clinical Center (CC)
Listed as NCT02771249, this PHASE1 trial focuses on HIV Infected Population With Latent Tuberculosis and remains completed. Sponsored by National Institutes of Health Clinical Center (CC), it has been updated 43 times since 2016, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Study Description(click to expand)Rifapentine (RPT) is a long-acting rifamycin that can be used weekly with isoniazid (INH) as a first-line regimen in the treatment of latent tuberculosis infection (LTBI). Although this regimen offers several potential benefits, the use of weekly RPT plus INH is not currently recommended in adults infected with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) due to limited evidence on drug interactions with antiretrovirals (ARVs).1Darunavir boosted with cobicistat (DRV/c) comprises part of alternative treatment regimens recommended for the treatment of HIV.2However, drug interactions between these ARV agents and RPT are of concern. Thus, the purpose of this study is to determine the effects of concomitant RPT and INH administration on the steady state PK of DRV/c. This is an open-label, fixed sequence, intrasubject drug-drug interaction study designed to evaluate the steady state PK of DRV/c with coadministration of once weekly RPT and INH given at doses used to treat LTBI. Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + (RPT and INH) once weekly (days 5-19). Participants in Arm B will undergo periodic serial ARV PK blood draws on days 4, 14, and 19. DRV/c PK parameters...
Rifapentine (RPT) is a long-acting rifamycin that can be used weekly with isoniazid (INH) as a first-line regimen in the treatment of latent tuberculosis infection (LTBI). Although this regimen offers several potential benefits, the use of weekly RPT plus INH is not currently recommended in adults infected with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) due to limited evidence on drug interactions with antiretrovirals (ARVs).1Darunavir boosted with cobicistat (DRV/c) comprises part of alternative treatment regimens recommended for the treatment of HIV.2However, drug interactions between these ARV agents and RPT are of concern. Thus, the purpose of this study is to determine the effects of concomitant RPT and INH administration on the steady state PK of DRV/c.
This is an open-label, fixed sequence, intrasubject drug-drug interaction study designed to evaluate the steady state PK of DRV/c with coadministration of once weekly RPT and INH given at doses used to treat LTBI. Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + (RPT and INH) once weekly (days 5-19). Participants in Arm B will undergo periodic serial ARV PK blood draws on days 4, 14, and 19.
DRV/c PK parameters will be determined using non-compartmental methods. Cobicistat levels will only be assessed if DRV concentrations are significantly decreased. The following PK parameters will be compared between phases: area under the curve over the dosing interval, maximum plasma concentration, time to maximum plasma concentration, terminal half-life, apparent oral clearance, and minimum plasma concentration. Adverse events will be graded and recorded.
Status Flow
Change History
43 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2022 — May 2022 [monthly]
Completed PHASE1
▶ Show 38 earlier versions
-
Jan 2022 — Apr 2022 [monthly]
Completed PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Completed PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Completed PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE1
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Oct 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE1
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Apr 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
May 2017 — Aug 2017 [monthly]
Suspended PHASE1
-
Feb 2017 — May 2017 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institutes of Health Clinical Center (CC)
For direct contact, visit the study record on ClinicalTrials.gov .